A review on electronic nose for diagnosis and monitoring treatment response in lung cancer

J Breath Res. 2023 Mar 27;17(2). doi: 10.1088/1752-7163/acb791.

Abstract

Lung cancer is one of the common malignancies with high mortality rate and a poor prognosis. Most lung cancer cases are diagnosed at an advanced stage either due to limited resources of infrastructure, trained human resources, or delay in clinical suspicion. Low-dose computed tomography has emerged as a screening tool for lung cancer detection but this may not be a feasible option for most developing countries. Electronic nose is a unique non-invasive device that has been developed for lung cancer diagnosis and monitoring response by exhaled breath analysis of volatile organic compounds. The breath-print have been shown to differ not only among lung cancer and other respiratory diseases, but also between various types of lung cancer. Hence, we postulate that the breath-print analysis by electronic nose could be a potential biomarker for the early detection of lung cancer along with monitoring treatment response in a resource-limited setting. In this review, we have consolidated the current published literature suggesting the use of an electronic nose in the diagnosis and monitoring treatment response of lung cancer.

Keywords: VOCs; biomarker; eNOSE; exhaled breath analysis; lung cancer.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / analysis
  • Breath Tests / methods
  • Electronic Nose
  • Exhalation
  • Humans
  • Lung Neoplasms* / diagnostic imaging
  • Lung Neoplasms* / therapy
  • Volatile Organic Compounds* / analysis

Substances

  • Biomarkers
  • Volatile Organic Compounds